Innovation is the product of intentional human endeavor. Countries seeking world-leading innovative enterprises and industries need to implement thoughtful and effective national innovation systems, and supporting policy instruments, to maximize their innovation potential. Reports here review the innovation systems/policies of GTIPA-member nations.
This blueprint aims to inform European institutions on the state of innovation in three sectors (Digital, Healthcare, and Energy & Mobility).
The extent to which follow-on pharmaceutical innovations should be protectable by patents is hotly debated amongst the public health and IP community in Geneva. But are fears that follow-on patents simply extend indefinitely, or “evergreening,” medicine patents justified?
Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.
This report is one of the studies in Growth Analysis’ framework project: What role does the public sector have in large knowledge-intensive investments (LKI)? The overall aim of the framework project is to create learning regarding how the public sector can promote efficient processes for LKI.
Amid trade issues and the ongoing Fourth Industrial Revolution (4IR) the Korean economy is entering an era of low growth. In this era, Korea is facing crises and opportunities in terms of its industrial economy.
The federal government should take aggressive steps to spur the development of more tech hubs in America’s heartland by identifying promising metro areas and helping them transform into self-sustaining innovation centers.
Tax incentives can play an important role in accelerating the innovations needed for a low-carbon future, but only if the incentives reward innovators rather than support well-entrenched incumbents.
Using the eCl@ss Standard as an example, innovations are increasingly generated through networked research and cooperation that transcends company, industry and national boundaries.
The study analyses the Indian Biotechnology landscape and provides a roadmap for its future, starting with the rate of growth that is required to make it a $100 billion industry by 2025.
The maxim “you can’t manage what you can’t measure” has never been so relevant. The failure to effectively leverage data has undoubtedly cost many lives and caused severe social and economic damage to communities ravaged by opioid addiction.